Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own
Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.
You may also be interested in...
Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.
Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.
Among the many lessons that cancer drug sponsors should take away from the Avastin proceedings is that if they hope to secure approval on the basis of a progression-free survival endpoint, in certain settings, they need to bolster that data with quality-of-life assessments.